Literature DB >> 985824

Recurrent goiter, hyperthyroidism, galactorrhea and amenorrhea due to a thyrotropin and prolactin-producing pituitary tumor.

K Horn, F Erhardt, R Fahlbusch, C R Pickardt, K V Werder, P C Scriba.   

Abstract

A 22-year-old woman with recurrent goiter, hyperthyroidism, galactorrhea, and amenorrhea due to a pituitary tumor is described. She had been treated surgically twice for recurrent goiter with tracheal compression. Despite clinical signs of hyperthyroidism and slightly elevated plasma thyroid hormone levels (T4: 11 mug/dl; T3: 189 ng/dl), without thyroid hormone replacement therapy the basal TSH level was elevated up to 23 muU/ml and could not be suppressed by exogenous thyroid hormones: even when the serum thyroid hormone levels were raised into the thyrotoxic range (T4: 16.2 mug/dl T3: 392 ng/dl), the basal TSH fluctuated between 12 and 29 muU/ml. The basal PRL level was elevated up to 6000 muU/ml. The administration of TRH (200 mug iv) led only to small increments of TSH and PRL levels. Bromocriptin (5 mg p.o.) or l-dopa (0.5 g p.o.) suppressed TSH and PRL values significantly. After transsphenoidal hypophysectomy, TSH and PRL were below normal and the patient development panhypopituitarism. The adenoma showed two cell types which could be identified as lactotrophs and thyrotrophs by electronmicroscopy and immunofluorescence. From these data we conclude that the patient had a pituitary tumor with an overproduction of thyrotropin and prolactin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 985824     DOI: 10.1210/jcem-43-1-137

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Two-step development of a pituitary adenoma: from hyperprolactinemic syndrome to Cushing's disease.

Authors:  R G Gheri; W Boddi; F Ammannati; J Olivotto; C Nozzoli; A Franchi; L Bordi; M L Luisi; P Mennonna
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

2.  Familial inappropriate TSH secretion: evidence suggesting a dissociated pituitary resistance to T3 and T4.

Authors:  J L Vandalem; G Pirens; G Hennen
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

3.  Hyperthyroidism due to a thyrotropin secreting pituitary adenoma.

Authors:  J P McCann; J K Nelson
Journal:  Ir J Med Sci       Date:  1985-09       Impact factor: 1.568

4.  Heterogeneous pituitary adenomas. A light microscopic, immunohistochemical and electron microscopic study.

Authors:  D Martinez; D Barthe
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

5.  Hyperthyroidism due to inappropriate TSH secretion with associated hyperprolactinaemia--a case report and review of the literature.

Authors:  I M Spitz; M Sheinfeld; B Glasser; H J Hirsch
Journal:  Postgrad Med J       Date:  1984-05       Impact factor: 2.401

6.  In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine.

Authors:  A Spada; M Bassetti; E Martino; G Giannattasio; P Beck-Peccoz; A Sartorio; L Vallar; L Baschieri; A Pinchera; G Faglia
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

7.  Abnormal thyroid stimulating hormone following pituitary surgery.

Authors:  G K Worth; R W Retallack; D H Gutteridge
Journal:  J Endocrinol Invest       Date:  1981 Apr-Jun       Impact factor: 4.256

8.  Pituitary adenomas with hyperfunction of TSH. Frequency, histological classification, immunocytochemistry and ultrastructure.

Authors:  W Saeger; D K Lüdecke
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

9.  Treatment of patients with prolactinomas.

Authors:  K v Werder; R Fahlbusch; R Landgraf; C R Pickardt; H K Rjosk; P C Scriba
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

10.  Argyrophil pituitary tumors showing TSH cells or small granule cells.

Authors:  C Capella; L Usellini; B Frigerio; R Buffa; P Fontana; E Solcia
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1979-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.